Showing results (61-70 of 104) with videos related to

Sort By:
Pageof 11
Annals of the Rheumatic Diseases|May 8, 2010
Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritisMonika Schoels, John Wong, David L Scott, et al.
Rheumatology (Oxford, England)|November 21, 2019
Obesity reduces the real-world effectiveness of cytokine-targeted but not cell-targeted disease-modifying agents in rheumatoid arthritisMartin Schäfer, Yvette Meißner, Jörn Kekow, et al.
Rheumatology International|November 17, 2017
Long-term effectiveness of tocilizumab in patients with rheumatoid arthritis, stratified by number of previous treatment failures with biologic agents: results from the German RABBIT cohortLisa Baganz, Adrian Richter, Jörn Kekow, et al.
Clinical and Experimental Rheumatology|April 6, 2013
Comorbidity profiles among adult patients with juvenile idiopathic arthritis: results of a biologic registerAnna Raab, Claudia Sengler, Martina Niewerth, et al.
Arthritis Research & Therapy|January 13, 2010
Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBITAnja Strangfeld, Franka Hierse, Rolf Rau, et al.
Rheumatology (Oxford, England)|May 24, 2015
Health-related quality of life in patients with long-standing rheumatoid arthritis in the era of biologics: data from the German biologics register RABBITKerstin Gerhold, Adrian Richter, Matthias Schneider, et al.
RMD Open|November 5, 2015
Trends in treatment and outcomes of ankylosing spondylitis in outpatient rheumatological care in Germany between 2000 and 2012Dörte Huscher, Katja Thiele, Martin Rudwaleit, et al.
Pharmacoeconomics|April 28, 2005
Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany: I. Selected DMARDs and patient-related costsPeter K Schädlich, Henning Zeidler, Angela Zink, et al.
Pharmacoeconomics|April 28, 2005
Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide for rheumatoid arthritis in Germany: II. The contribution of leflunomide to efficiencyPeter K Schädlich, Henning Zeidler, Angela Zink, et al.
Arthritis and Rheumatism|November 1, 2006
Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trialsAngela Zink, Anja Strangfeld, Matthias Schneider, et al.
Pageof 11